CLINICAL TRIALS PROFILE FOR KAYEXALATE

All Clinical Trials for KAYEXALATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01011699 ↗	Nicotinamide Versus Sevelamer Hydrochloride on Phosphatemia Control on Chronic Hemodialysed Patients	Terminated	Centre Hospitalier Universitaire, Amiens	Phase 3	2010-01-01	The comparison between nicotinamide and sevelamer aims to demonstrate, in chronic hemodialysed patients, the non-inferiority of nicotinamide in terms of control of the phosphatemia. Secondary objectives is to compare the two treatments in terms of efficiency in other biological parameters, vascular calcification and bone mass loss and on the clinical and biological tolerance and finally to explore the roles of metabolites of nicotinamide.
NCT02065076 ↗	Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients	Completed	Department of Pharmacy, Maisonneuve Rosemont Hospital	Phase 4	2014-02-01	The purpose of this trial is to determine if sodium polystyrene sulfonate (SPS) is an effective treatment of mild hyperkalemia in chronic kidney disease patients followed at a pre-dialysis or nephrology outpatient clinic. Subjects will be randomized to one of two treatment arms: 30 g of placebo or SPS to be taken orally once daily for seven days. The change in serum potassium levels will be compared in both treatment groups. The proportion of subjects attaining normokalemia (3.5 to 5.0 mmol/L) after seven days of treatment will also be compared. Finally, side effects will be reported for each treatment arm.
NCT02065076 ↗	Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients	Completed	Nephrology Research Axis of Maisonneuve Rosemont Hospital	Phase 4	2014-02-01	The purpose of this trial is to determine if sodium polystyrene sulfonate (SPS) is an effective treatment of mild hyperkalemia in chronic kidney disease patients followed at a pre-dialysis or nephrology outpatient clinic. Subjects will be randomized to one of two treatment arms: 30 g of placebo or SPS to be taken orally once daily for seven days. The change in serum potassium levels will be compared in both treatment groups. The proportion of subjects attaining normokalemia (3.5 to 5.0 mmol/L) after seven days of treatment will also be compared. Finally, side effects will be reported for each treatment arm.
NCT02065076 ↗	Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients	Completed	Université de Montréal	Phase 4	2014-02-01	The purpose of this trial is to determine if sodium polystyrene sulfonate (SPS) is an effective treatment of mild hyperkalemia in chronic kidney disease patients followed at a pre-dialysis or nephrology outpatient clinic. Subjects will be randomized to one of two treatment arms: 30 g of placebo or SPS to be taken orally once daily for seven days. The change in serum potassium levels will be compared in both treatment groups. The proportion of subjects attaining normokalemia (3.5 to 5.0 mmol/L) after seven days of treatment will also be compared. Finally, side effects will be reported for each treatment arm.
NCT02065076 ↗	Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Pre-dialysis Patients	Completed	Maisonneuve-Rosemont Hospital	Phase 4	2014-02-01	The purpose of this trial is to determine if sodium polystyrene sulfonate (SPS) is an effective treatment of mild hyperkalemia in chronic kidney disease patients followed at a pre-dialysis or nephrology outpatient clinic. Subjects will be randomized to one of two treatment arms: 30 g of placebo or SPS to be taken orally once daily for seven days. The change in serum potassium levels will be compared in both treatment groups. The proportion of subjects attaining normokalemia (3.5 to 5.0 mmol/L) after seven days of treatment will also be compared. Finally, side effects will be reported for each treatment arm.
NCT04585542 ↗	Comparison of Potassium Binders in the ER	Recruiting	University of California, Irvine	Phase 4	2020-10-20	Compare efficacy of 3 oral potassium binders (cation exchange resins) on lowering blood potassium, in patients presenting to the Emergency Room with acute hyperkalemia.

Clinical Trial Conditions for KAYEXALATE

Condition Name

Condition Name for KAYEXALATE
Intervention	Trials
Oral Potassium Binders	1
Acute Hyperkalemia	1
Chronic Kidney Failure	1
Chronic Renal Failure	1

Condition MeSH

Condition MeSH for KAYEXALATE
Intervention	Trials
Hyperkalemia	2
Renal Insufficiency	2
Kidney Failure, Chronic	2

Clinical Trial Locations for KAYEXALATE

Trials by Country

Trials by Country for KAYEXALATE
Location	Trials
France	11
United States	1
Canada	1

Trials by US State

Trials by US State for KAYEXALATE
Location	Trials
California	1

Clinical Trial Progress for KAYEXALATE

Clinical Trial Phase

Clinical Trial Phase for KAYEXALATE
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	1

Clinical Trial Status

Clinical Trial Status for KAYEXALATE
Clinical Trial Phase	Trials
Completed	1
Recruiting	1
Terminated	1

Clinical Trial Sponsors for KAYEXALATE

Sponsor Name

Sponsor Name for KAYEXALATE
Sponsor	Trials
Maisonneuve-Rosemont Hospital	1
University of California, Irvine	1
Centre Hospitalier Universitaire, Amiens	1

Sponsor Type

Sponsor Type for KAYEXALATE
Sponsor	Trials
Other	6